CL2020000553A1 - Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. - Google Patents

Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.

Info

Publication number
CL2020000553A1
CL2020000553A1 CL2020000553A CL2020000553A CL2020000553A1 CL 2020000553 A1 CL2020000553 A1 CL 2020000553A1 CL 2020000553 A CL2020000553 A CL 2020000553A CL 2020000553 A CL2020000553 A CL 2020000553A CL 2020000553 A1 CL2020000553 A1 CL 2020000553A1
Authority
CL
Chile
Prior art keywords
cycloolefin
substituted heteroaromatic
heteroaromatic compounds
same
enanthomers
Prior art date
Application number
CL2020000553A
Other languages
English (en)
Spanish (es)
Inventor
Guangxiu Dai
Wei-Guo Su
Kun Xiao
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CL2020000553A1 publication Critical patent/CL2020000553A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2020000553A 2017-09-07 2020-03-05 Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso. CL2020000553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途

Publications (1)

Publication Number Publication Date
CL2020000553A1 true CL2020000553A1 (es) 2020-08-07

Family

ID=65634832

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000553A CL2020000553A1 (es) 2017-09-07 2020-03-05 Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.

Country Status (19)

Country Link
US (3) US11414390B2 (enExample)
EP (1) EP3679020A4 (enExample)
JP (2) JP7273030B6 (enExample)
KR (1) KR102566237B1 (enExample)
CN (6) CN109467538A (enExample)
AR (1) AR112794A1 (enExample)
AU (1) AU2018329047B2 (enExample)
CA (1) CA3073782A1 (enExample)
CL (1) CL2020000553A1 (enExample)
EA (1) EA202090653A1 (enExample)
IL (1) IL272923B2 (enExample)
MX (1) MX2020002505A (enExample)
PE (1) PE20200727A1 (enExample)
PH (1) PH12020500408A1 (enExample)
SG (1) SG11202001642WA (enExample)
TW (1) TWI816693B (enExample)
UA (1) UA129118C2 (enExample)
WO (1) WO2019047909A1 (enExample)
ZA (1) ZA202001448B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
CN116209655A (zh) * 2020-11-09 2023-06-02 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
CN118355008A (zh) * 2022-01-11 2024-07-16 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法
WO2026026904A1 (en) * 2024-08-01 2026-02-05 Hutchmed Limited The crystalline forms of a compound

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US7467603B2 (en) 2004-05-24 2008-12-23 Equusys, Incorporated Animal instrumentation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
EP2066645A2 (en) 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
EP2588471A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
HRP20171554T1 (hr) 2011-09-12 2017-11-17 Merck Patent Gmbh Novi imidazol amini kao modulatori aktivnosti kinaze
ES2646759T3 (es) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
JP6479667B2 (ja) * 2012-10-24 2019-03-06 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 除草性アジン
CN103044469A (zh) 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
US9862692B2 (en) 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX375030B (es) * 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
DK3063143T3 (en) 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
KR102526632B1 (ko) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
WO2016119707A1 (en) * 2015-01-29 2016-08-04 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
AU2016299092B2 (en) 2015-07-30 2020-08-20 Centaurus Biopharma Co., Ltd. 1, 3, 5-triazine derivative and method of using same
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
WO2017096945A1 (zh) 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
TWI707859B (zh) 2017-09-07 2020-10-21 日商衛材R&D企管股份有限公司 五環化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof
US12616690B2 (en) 2017-09-07 2026-05-05 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Also Published As

Publication number Publication date
JP2020533319A (ja) 2020-11-19
CN117024363A (zh) 2023-11-10
US12234211B2 (en) 2025-02-25
US20250223267A1 (en) 2025-07-10
JP7273030B2 (ja) 2023-05-12
ZA202001448B (en) 2024-11-27
AR112794A1 (es) 2019-12-11
EP3679020A4 (en) 2021-05-05
US20210163426A1 (en) 2021-06-03
JP7603740B2 (ja) 2024-12-20
UA129118C2 (uk) 2025-01-22
JP2023103290A (ja) 2023-07-26
CN117257809B (zh) 2026-08-11
NZ762447A (en) 2023-09-29
SG11202001642WA (en) 2020-03-30
CN109467538A (zh) 2019-03-15
MX2020002505A (es) 2020-07-20
US20210363115A2 (en) 2021-11-25
AU2018329047A1 (en) 2020-03-12
US20220372005A1 (en) 2022-11-24
WO2019047909A1 (en) 2019-03-14
EP3679020A1 (en) 2020-07-15
CN111132967B (zh) 2023-08-04
CA3073782A1 (en) 2019-03-14
CN116999441B (zh) 2026-07-10
PE20200727A1 (es) 2020-07-23
AU2018329047B2 (en) 2023-09-07
PH12020500408A1 (en) 2021-03-01
TWI816693B (zh) 2023-10-01
US11414390B2 (en) 2022-08-16
CN117797156A (zh) 2024-04-02
KR102566237B1 (ko) 2023-08-14
TW201912632A (zh) 2019-04-01
BR112020004563A2 (pt) 2020-09-08
JP7273030B6 (ja) 2024-02-15
EA202090653A1 (ru) 2021-02-03
CN116999441A (zh) 2023-11-07
KR20200052321A (ko) 2020-05-14
CN117257809A (zh) 2023-12-22
IL272923B2 (en) 2023-06-01
IL272923A (en) 2020-04-30
CN111132967A (zh) 2020-05-08

Similar Documents

Publication Publication Date Title
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
CY1124837T1 (el) Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
GEAP202215535A (en) Compounds
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
MX392601B (es) Análogos sintéticos de las ecteinascidinas y su uso como agentes antitumorales.
GEP20237506B (en) Pcsk9 antagonist compounds
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MD3405471T2 (ro) Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
MX2017011024A (es) Desacetoxitubulisina h y analogos de esta.
UY36257A (es) “compuestos de imidazopiridazina”.
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
PH12020500408A1 (en) Cycloolefin substituted heteroaromatic compounds and their use